Estimation of Kidney Function Through Combination of Renal Biomarkers in Blood and Urine of Healthy Infants and Children
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Renal Biomarkers in Children
- Sponsor
- University Hospital, Basel, Switzerland
- Enrollment
- 158
- Locations
- 1
- Primary Endpoint
- Serum concentration of cystatin C (mg/l)
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
To characterize the relationship of renal biomarkers (Creatinine, albumin, Cystatin C, NGAL, beta-trace protein, beta-2 microglobulin, and uromodulin) between each other and the variation over age, measured in serum and urine of healthy children. Unused residual blood and urine samples will be used for testing the renal Parameters.
Detailed Description
Despite relevant research in renal biomarkers, there is currently no optimal marker available that reliably quantifies kidney function and indicates kidney injury in its early stages. The combination of two or more biomarkers might be a more promising approach than investigating a single parameter. The relationship of renal biomarkers (creatinine, albumin, Cystatin C, NGAL, beta-trace protein, beta-2 microglobulin, and uromodulin) between each other and the variation over age in infants and children (without chronic kidney disease) is investigated. The biomarkers in urine samples are explored to find less invasive means of quantifying renal health. Patients between the age of 0 and 12 years undergoing blood with or without urine sampling as part of their diagnostic workup are eligible for the study. Unused residual blood and urine samples will be used for testing the renal parameters.
Investigators
Eligibility Criteria
Inclusion Criteria
- •healthy patients for elective surgery, requiring venous access via peripheral venous canula
Exclusion Criteria
- •chronic kidney disease
- •acute kidney failure (stage 2 or above as defined by Kidney Disease Improving Global Outcomes (KDIGO) consensus 2012))
- •major haemorrhage
- •second or third degree burns
- •liver failure
- •chronic diseases with effecting the kidney (systemic lupus erythematosus, amyloidosis)
Outcomes
Primary Outcomes
Serum concentration of cystatin C (mg/l)
Time Frame: single point in time at subject enrollment
blood test for renal biomarker
Serum concentration of creatinine (ymol/l)
Time Frame: single point in time at subject enrollment
blood test for renal biomarker
Serum concentration of Neutrophil gelatinase-associated lipocalin (ng/ml)
Time Frame: single point in time at subject enrollment
blood test for renal biomarker
Serum concentration of beta-trace Protein (mg/l)
Time Frame: single point in time at subject enrollment
blood test for renal biomarker
Serum concentration of beta-2 Microglobulin (mg/l)
Time Frame: single point in time at subject enrollment
blood test for renal biomarker
Serum concentration of Uromodulin (ng/ml)
Time Frame: single point in time at subject enrollment
blood test for renal biomarker
Urine concentration of creatinine (mmols/kg/24h)
Time Frame: single point in time at subject enrollment
Urine test for renal biomarker
Urine concentration of cystatin C (mg/l)
Time Frame: single point in time at subject enrollment
Urine test for renal biomarker
Urine concentration of Neutrophil gelatinase-associated lipocalin (yg/l)
Time Frame: single point in time at subject enrollment
Urine test for renal biomarker
Urine concentration of beta-trace Protein (mg/l)
Time Frame: single point in time at subject enrollment
Urine test for renal biomarker
Urine concentration of beta-2 microglobulin (mg/l)
Time Frame: single point in time at subject enrollment
Urine test for renal biomarker
Urine concentration of uromodulin (ng/ml)
Time Frame: at time of enrollment
Urine test for renal biomarker
Urine concentration of Albumin (mg/l)
Time Frame: at time of enrollment
Urine test for renal biomarker
Plasma protein binding of survival motor neuron (SMN) 2 splicing modifiers
Time Frame: single point in time at subject enrollment
blood test for spinal muscular atrophy